Rose Goldstein
YOU?
Author Swipe
View article: Phase I trial of a novel hTERT vaccination strategy addressing T effector cells and immune-suppressor mechanisms
Phase I trial of a novel hTERT vaccination strategy addressing T effector cells and immune-suppressor mechanisms Open
Background: Inability to generate activated T effector cells and the presence of strong suppressor mechanisms have limited cancer vaccine efficacy. Human telomerase reverse transcriptase (hTERT) is expressed in > 90% of tumours but is HLA …